Literature DB >> 17804643

Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum.

John A H Hoerter1, Nils G Walter.   

Abstract

Small interfering (si)RNAs have recently been used to therapeutically silence genes in vivo after intravenous systemic delivery. Further progress in the development of siRNA therapeutics will in part rely on tailoring site-specific chemical modifications of siRNAs to optimize their pharmacokinetic properties. Advances are particularly needed to improve the nucleolytic stability of these double-stranded RNA drugs in vivo and suppress adverse off-target gene silencing effects. Here we demonstrate that specific chemical 2'-O-methylation, which has already been shown to ameliorate the omnipresent off-target toxicity of siRNAs, selectively protects the particularly vulnerable 5'-end of the guide strand against exonucleolytic degradation in human blood serum. Specific chemical modification thus resolves the asymmetric degradation of the guide and passenger strands, which is inherent to the thermodynamic asymmetry of the siRNA termini as required for proper utilization of the guide strand in RNA interference.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17804643      PMCID: PMC2040087          DOI: 10.1261/rna.602307

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  35 in total

1.  Ribonuclease A.

Authors:  Ronald T. Raines
Journal:  Chem Rev       Date:  1998-05-07       Impact factor: 60.622

2.  RNA interference in mammalian cells by chemically-modified RNA.

Authors:  Dwaine A Braasch; Susan Jensen; Yinghui Liu; Kiran Kaur; Khalil Arar; Michael A White; David R Corey
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

Review 3.  Small non-coding RNAs as magic bullets.

Authors:  Fritz Eckstein
Journal:  Trends Biochem Sci       Date:  2005-08       Impact factor: 13.807

Review 4.  Illuminating the silence: understanding the structure and function of small RNAs.

Authors:  Tariq M Rana
Journal:  Nat Rev Mol Cell Biol       Date:  2007-01       Impact factor: 94.444

5.  Gene silencing activity of siRNAs with a ribo-difluorotoluyl nucleotide.

Authors:  Jie Xia; Anne Noronha; Ivanka Toudjarska; Feng Li; Akin Akinc; Ravi Braich; Maria Frank-Kamenetsky; Kallanthottathil G Rajeev; Martin Egli; Muthiah Manoharan
Journal:  ACS Chem Biol       Date:  2006-04-25       Impact factor: 5.100

Review 6.  On the art of identifying effective and specific siRNAs.

Authors:  Yi Pei; Thomas Tuschl
Journal:  Nat Methods       Date:  2006-09       Impact factor: 28.547

7.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

Authors:  Charles R Allerson; Namir Sioufi; Russell Jarres; Thazha P Prakash; Nishant Naik; Andres Berdeja; Lisa Wanders; Richard H Griffey; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

8.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

9.  Terbium-mediated footprinting probes a catalytic conformational switch in the antigenomic hepatitis delta virus ribozyme.

Authors:  Dinari A Harris; Rebecca A Tinsley; Nils G Walter
Journal:  J Mol Biol       Date:  2004-08-06       Impact factor: 5.469

10.  Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues.

Authors:  Salvatore Sorrentino; Mariarosaria Naddeo; Aniello Russo; Giuseppe D'Alessio
Journal:  Biochemistry       Date:  2003-09-02       Impact factor: 3.162

View more
  22 in total

1.  The design and screening of drugs to prevent acquired sensorineural hearing loss.

Authors:  Debashree Mukherjea; Leonard P Rybak; Kelly E Sheehan; Tejbeer Kaur; Vickram Ramkumar; Sarvesh Jajoo; Sandeep Sheth
Journal:  Expert Opin Drug Discov       Date:  2011-03-15       Impact factor: 6.098

Review 2.  Effect of surface properties on liposomal siRNA delivery.

Authors:  Yuqiong Xia; Jie Tian; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2015-12-02       Impact factor: 12.479

Review 3.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

4.  Viral RNAi suppressor reversibly binds siRNA to outcompete Dicer and RISC via multiple turnover.

Authors:  Renata A Rawlings; Vishalakshi Krishnan; Nils G Walter
Journal:  J Mol Biol       Date:  2011-02-24       Impact factor: 5.469

5.  Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes.

Authors:  Wade W Grabow; Paul Zakrevsky; Kirill A Afonin; Arkadiusz Chworos; Bruce A Shapiro; Luc Jaeger
Journal:  Nano Lett       Date:  2011-01-13       Impact factor: 11.189

6.  Probing the inherent stability of siRNA immobilized on nanoparticle constructs.

Authors:  Stacey N Barnaby; Andrew Lee; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-19       Impact factor: 11.205

Review 7.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

Review 8.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

Review 9.  MicroRNAs, cancer and cancer stem cells.

Authors:  Amy L Zimmerman; Shiyong Wu
Journal:  Cancer Lett       Date:  2010-10-20       Impact factor: 8.679

10.  Promiscuous 8-alkoxyadenosines in the guide strand of an siRNA: modulation of silencing efficacy and off-pathway protein binding.

Authors:  Uday Ghanty; Erik Fostvedt; Rachel Valenzuela; Peter A Beal; Cynthia J Burrows
Journal:  J Am Chem Soc       Date:  2012-10-11       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.